(Q35007337)

5 August 2017

1 reference

title

Denileukin diftitox: a novel immunotoxin (English)

1 reference

5 August 2017

George Manoukian

1

1 reference

5 August 2017

Fred Hagemeister

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Expert Opinion on Biological Therapy

5 August 2017

published in

1 reference

5 August 2017

volume

9

1 reference

5 August 2017

issue

11

1 reference

5 August 2017

page(s)

1445-1451

1 reference

DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712590903348135

The structure of IL2 bound to the three chains of the IL2 receptor and how signaling occurs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903348135

The IL-2 receptor complex: its structure, function, and target genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903348135

Denileukin diftitox: a concise clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903348135

Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903348135

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903348135

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903348135

Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903348135

DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903348135

Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903348135

Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903348135

Transient T cell depletion causes regression of melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903348135

Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903348135

Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903348135

Regulatory T cells in ovarian cancer: biology and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903348135

Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903348135

Enhanced interleukin-2 diphtheria toxin conjugate-induced growth suppression in retinoic acid-treated hypoxic hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903348135

10.1517/14712590903348135

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference